Stocktoria
Keros Therapeutics, Inc. KROS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-04-08
Chart by TradingView
6/9
Piotroski F — financial health
11.55
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $244.1M | $0 | $151,000 | $0 | $20.1M |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M |
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M |
| Shareholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M |
| Ratios | |||||
| Operating margin | 27.7% | — | -112543.7% | — | -280.5% |
| Net margin | 35.7% | — | -101319.2% | — | -292.3% |
| FCF margin | 43.4% | — | -84087.4% | — | -314.3% |
| Return on assets | 25.7% | -30.4% | -41.3% | -34.1% | -23.0% |
| Return on equity | 28.7% | -32.8% | -46.1% | -37.7% | -24.2% |
| Current ratio | 15.45 | 21.45 | 14.25 | 17.27 | 21.23 |
| Revenue growth | — | -100.0% | — | -100.0% | — |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 453,482 | $5.0M |
| Point72 Asset Management, L.P. | 109,015 | $1.2M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 11.55 (safe)
- Working capital / assets 0.873
- Retained earnings / assets -1.425
- EBIT / assets 0.2
- Equity / liabilities 8.688
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001664710 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.